Axon Enterprise, Inc $AXON Stock Holdings Lifted by Knollwood Investment Advisory LLC

Knollwood Investment Advisory LLC raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 26.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,969 shares of the biotechnology company’s stock after buying an additional 1,232 shares during the period. Knollwood Investment Advisory LLC’s holdings in Axon Enterprise were worth $3,346,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of AXON. BlackRock Inc. raised its position in shares of Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after purchasing an additional 345,365 shares during the period. Geode Capital Management LLC increased its stake in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after purchasing an additional 35,544 shares in the last quarter. Sands Capital Management LLC increased its stake in Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after purchasing an additional 167,095 shares in the last quarter. Wellington Management Group LLP raised its holdings in Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares during the period. Finally, Edgewood Management LLC purchased a new stake in Axon Enterprise during the fourth quarter valued at about $846,516,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on AXON. Piper Sandler boosted their price target on shares of Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $700.00 price objective on shares of Axon Enterprise in a research note on Thursday, June 25th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. Finally, Morgan Stanley increased their target price on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $721.57.

Insider Activity

In other news, insider Jeffrey Kunins sold 9,605 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the transaction, the insider directly owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This represents a 8.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Smith sold 10,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $643.79, for a total value of $6,437,900.00. Following the sale, the chief executive officer owned 3,040,997 shares of the company’s stock, valued at approximately $1,957,763,458.63. This represents a 0.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 56,380 shares of company stock worth $32,582,366 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise Price Performance

Shares of AXON opened at $538.15 on Friday. The business’s 50-day moving average is $568.46 and its 200-day moving average is $486.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The company has a market capitalization of $43.72 billion, a price-to-earnings ratio of 223.30, a P/E/G ratio of 8.23 and a beta of 1.40. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $792.16.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. During the same period in the previous year, the firm posted $2.12 earnings per share. The firm’s revenue was up 35.3% on a year-over-year basis. Equities research analysts expect that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.